At a glance: 8 S&P 500 names report today — all after the close except Smucker (premarket) — headlined by Nvidia, with CrowdStrike, Salesforce, Synopsys, Agilent, Veeva, HP and Smucker's rounding out the year's heaviest single-day slate this earnings season.

Note: some figures were unavailable in today's data build — one previously previewed name had to be scored from a secondary source instead of the earnings calendar, so treat any gaps as a data limitation, not a quiet print.

The tape ahead

Nvidia headlines the busiest session of the summer, reporting fiscal Q2 after the close with consensus at $2.09 (range $2.05–$2.23 across 41 estimates) and the options market pricing a 5.92% move against just a 1.59% average realized swing over the last eight prints — by far the widest implied/realized gap on tonight's slate, priced for genuine event risk. Both lines point the same direction: consensus implies low-double-digit sequential growth versus the prior quarter (up 12% vs prev.Q. on EPS, up 13% vs prev.Q. on revenue), consistent with a name whose EPS growth has been running near 67% over the trailing year. The debate is Blackwell Ultra ramp health and whether hyperscaler orders show any early signs of digestion as the transition to Vera Rubin gets underway, gross margin trajectory as that mix shifts, and China, where H-series access remains gated by case-by-case export licensing and is largely excluded from guidance — any upside there is optionality, not baseline. Estimate revisions have drifted up rather than down into the print, and next quarter's guide may prove more market-moving than tonight's actuals given how much of the fiscal-year story is already known. Read-across runs squarely through HBM-supply-constrained memory names and the broader AI-infrastructure complex; the standing multi-year debate — custom hyperscaler silicon and AMD's MI-series eroding out-year share — is not this quarter's story. Options positioning skews toward hedged structures with dealers reportedly short gamma to the upside, a setup where a strong beat could mechanically amplify the move.

CrowdStrike also reports after the close, consensus at $0.29 (range $0.29–$0.30, 45 estimates) with an 8.23% implied move against a 1.79% realized average — rich pricing for a name that has beaten all eight of its last prints (last surprise +3.05%). Sequentially, consensus implies modest growth on both lines (up 4% vs prev.Q. on EPS, up 4% vs prev.Q. on revenue). The print is a referendum on whether the recent net-new-ARR reacceleration is durable platform consolidation or partly a Falcon Flex accounting artifact — Flex bundles multiple modules into one consumption commitment, which can smooth or front-load revenue recognition. The 2024 outage is largely a non-issue for retention at this point; the more interesting line is whether agentic/AI-native security products keep compounding as the standout growth driver. Competitively the setup looks clean, with no evidence of share loss to Microsoft Defender, Palo Alto or SentinelOne — a beat here would read as sector confirmation as much as company-specific strength.

Salesforce rounds out the software trio, consensus $3.27 (range $3.18–$3.47, 44 estimates) against a 7.38% implied move versus a 1.31% realized average — rich, though the stock's pattern of drawdowns despite beats (last surprise +24.07%, still an 88% beat rate) shows implied vol alone hasn't protected holders lately. Sequentially, EPS consensus implies a real step-down versus the prior quarter (down 16% vs prev.Q.) even as revenue implies modest growth (up 2% vs prev.Q.) — a gap worth watching for margin-mix commentary. The debate is whether Agentforce and Data Cloud can offset core Sales/Service Cloud deceleration; the market's central skepticism this year has been whether agentic AI cannibalizes per-seat SaaS pricing before Salesforce's own agent products monetize at scale, with Informatica integration the near-term swing factor on both revenue and margin. Read-across matters most for Workday, reporting tomorrow, and the broader question of whether enterprise software can show real AI monetization rather than merely offsetting core decay.

Synopsys reports after the close at a consensus of $3.67 (range $3.63–$3.78, 17 estimates), a 9.52% implied move against a 3.14% realized average, and an 88% beat rate. Sequentially both lines point higher (up 10% vs prev.Q. on EPS, up 7% vs prev.Q. on revenue), though trailing EPS growth has actually gone negative over the past year (-44.6%) even as the three-, five- and ten-year growth rates stay solidly positive (+8.5%, +13.5%, +18.9%) — a divergence best read as Ansys-related deal costs and amortization weighing on the trailing-year GAAP figure rather than a demand problem, with the multi-year trend intact. The debate is Ansys integration execution: the combined portfolio's first joint product release is already out, and the market wants confirmation that cross-sell and cost synergies are tracking the multi-year targets rather than merely existing. China remains a live wildcard given evolving export-control treatment of EDA tools. The sector tailwind is unambiguous — Cadence's own recent quarter showed record backlog on AI-driven design demand — so a soft print here would raise sector-demand questions rather than read as company-specific.

Agilent reports after the close at $1.49 consensus (range $1.43–$1.50, 17 estimates), an 8.14% implied move against a startlingly low 0.55% realized average — the cheapest-looking setup on tonight's slate given an 88% beat rate and a last surprise of +5.8%. Sequentially both lines are essentially flat versus the prior quarter (down 0.3% vs prev.Q. on EPS, up 0.4% vs prev.Q. on revenue), consistent with a business still climbing out of the life-science capex slowdown. The debate is whether that instrument-capex recovery is broadening: peers are diverging, with Thermo Fisher's analytical-instruments franchise inflecting positive while Danaher's life-sciences instruments still run slightly negative, and early-stage drug discovery the weakest pocket. Agilent's own China exposure has been a drag on recent quarters, so stabilization there matters more than the headline beat; diagnostics/genomics and the newly unified Advanced Therapeutics CDMO offering, aided by GLP-1-linked biomanufacturing demand, have been the consistent bright spots offsetting soft instruments.

Veeva reports after the close at $2.22 consensus (range $2.20–$2.27, 26 estimates), an 11.89% implied move — the richest premium on tonight's slate — against a 1.53% realized average and a perfect 100% beat rate (last surprise +4.91%). Sequentially both lines are roughly flat to modestly higher (down 0.8% vs prev.Q. on EPS, up 3% vs prev.Q. on revenue), a steadier setup than the headline growth rates suggest (EPS up 26% over the trailing year, accelerating to 31% over ten). The print turns on Vault CRM migration velocity — management has touted a high win rate and marquee large-pharma accounts already live on Vault — and any slippage in that pace would read as competitive vulnerability. Salesforce's re-entry into life-sciences CRM is the live threat, though a feared mass exodus hasn't materialized; Veeva's edge remains pharma-specific workflow depth against Salesforce's platform breadth and AI tooling.

HP reports after the close at just $0.69 consensus but an unusually wide $0.63–$1.00 range across 12 estimates — real dispersion in what the Street expects — and a 9.65% implied move against a 1.84% realized average. HP carries by far the weakest beat-rate history on tonight's slate (38% over the last eight prints, albeit with a sizeable last surprise of +20.26%), so market skepticism here is a standing feature, not new. Sequentially, EPS consensus implies a real step-down (down 20% vs prev.Q.) while revenue is essentially flat (down 0.1% vs prev.Q.) — a margin story more than a demand one. Personal Systems has been running hot on AI-PC mix and a Windows 11 refresh cycle, but rising memory/DRAM costs have become the dominant swing factor, with a margin trough previously flagged for later this fiscal year as pricing catches up to component inflation. Print remains the secular drag, supplies margin the offset; a clean margin trajectory, not just AI-PC unit growth, is what would change the narrative here.

J.M. Smucker opens the day before the bell, consensus $2.22 (range $2.18–$2.27, 14 estimates), a 7.18% implied move that sits close to its own 6.71% realized average — one of the smaller implied/realized gaps on the calendar — and a 75% beat rate. Sequentially both lines point lower (down 20% vs prev.Q. on EPS, down 6% vs prev.Q. on revenue). Coffee pricing is the swing segment: elevated green-coffee costs pushed full-year pricing sharply higher last year, with management guiding to cost relief this year, so today's print is an early read on whether volume elasticity is turning less negative as that relief shows up. Hostess/sweet baked goods remains the problem child amid SKU rationalization and GLP-1-related snacking softness, while pet food (Meow Mix, Milk-Bone) has been the steadier margin performer. This is as much a read on consumer price tolerance across packaged food broadly as it is on Smucker specifically.

Scorecard — reported since we last wrote

Just one name to score against Monday's edition. Intuit beat consensus EPS by 12.3%, but shares were roughly flat after hours (-0.4%) — a muted reaction that reads like the market looking past the beat to a softer forward guide and a newly announced restructuring effort rather than rewarding the print itself. Reported EPS fell sharply versus the prior quarter (-68.5%), but that's Intuit's usual seasonal pattern — fiscal Q3 carries the bulk of tax-season revenue, so fiscal Q4 is structurally the company's smallest quarter — not a signal about the underlying business. Revenue actuals weren't available to score against consensus this time.

Rest of the week

After tonight's flood, Thursday brings a smaller enterprise-software-and-retail cluster: Marvell, Autodesk and Workday on the software/semi side, and Dollar General, Ulta, Best Buy and Hormel on the consumer side, closing out the week's calendar.

Informational only — not investment advice. Figures are consensus/estimates and option-implied values from public sources and may be revised.